Quantitative autoradiography of [3H]t-butylbicycloorthobenzoate binding to the gamma-aminobutyric acid receptorA complex. 1994

S Y Sakurai, and A Kume, and D E Burdette, and R L Albin
Department of Neurology, University of Michigan, Ann Arbor.

The picrotoxinin ligand [3H]t-butylbicycloorthobenzoate ([3H] TBOB) was evaluated as an autoradiographic ligand to study gamma-aminobutyric acidA (GABAA) receptors. Specific [3H]TBOB binding was approximately 80% of total binding, was saturable and identified a single population of binding sites with regional Kd approximating 30 nM. [3H]TBOB binding was inhibited by picrotoxin, isoguvacine and pregnenolone sulfate. The benzodiazepines clonazepam and zolpidem produced complex effects with concentration-dependent inhibition and enhancement of [3H] TBOB binding. [3H]TBOB binding was regionally heterogeneous with high levels of binding in globus pallidus and layer IV of neocortex, intermediate levels of binding in other neocortical laminae and the cerebellar molecular layer and low levels of binding in the striatum and septum. The regional distribution of [3H]TBOB binding correlated poorly with the regional distribution of [3H]muscimol binding, somewhat better with the regional distribution of [3H]flunitrazepam binding and [35S]t-butylbicyclophosphorothionate binding and quite well with the regional distribution of [3H]zolpidem binding. [3H]TBOB binding site autoradiography is a convenient technique for studying GABAA receptor pharmacology in a regionally specific manner.

UI MeSH Term Description Entries
D008297 Male Males
D010852 Picrotoxin A mixture of PICROTOXININ and PICROTIN that is a noncompetitive antagonist at GABA-A receptors acting as a convulsant. Picrotoxin blocks the GAMMA-AMINOBUTYRIC ACID-activated chloride ionophore. Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9S*))-, compd. with (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8,Cocculin
D011963 Receptors, GABA-A Cell surface proteins which bind GAMMA-AMINOBUTYRIC ACID and contain an integral membrane chloride channel. Each receptor is assembled as a pentamer from a pool of at least 19 different possible subunits. The receptors belong to a superfamily that share a common CYSTEINE loop. Benzodiazepine-Gaba Receptors,GABA-A Receptors,Receptors, Benzodiazepine,Receptors, Benzodiazepine-GABA,Receptors, Diazepam,Receptors, GABA-Benzodiazepine,Receptors, Muscimol,Benzodiazepine Receptor,Benzodiazepine Receptors,Benzodiazepine-GABA Receptor,Diazepam Receptor,Diazepam Receptors,GABA(A) Receptor,GABA-A Receptor,GABA-A Receptor alpha Subunit,GABA-A Receptor beta Subunit,GABA-A Receptor delta Subunit,GABA-A Receptor epsilon Subunit,GABA-A Receptor gamma Subunit,GABA-A Receptor rho Subunit,GABA-Benzodiazepine Receptor,GABA-Benzodiazepine Receptors,Muscimol Receptor,Muscimol Receptors,delta Subunit, GABA-A Receptor,epsilon Subunit, GABA-A Receptor,gamma-Aminobutyric Acid Subtype A Receptors,Benzodiazepine GABA Receptor,Benzodiazepine Gaba Receptors,GABA A Receptor,GABA A Receptor alpha Subunit,GABA A Receptor beta Subunit,GABA A Receptor delta Subunit,GABA A Receptor epsilon Subunit,GABA A Receptor gamma Subunit,GABA A Receptor rho Subunit,GABA A Receptors,GABA Benzodiazepine Receptor,GABA Benzodiazepine Receptors,Receptor, Benzodiazepine,Receptor, Benzodiazepine-GABA,Receptor, Diazepam,Receptor, GABA-A,Receptor, GABA-Benzodiazepine,Receptor, Muscimol,Receptors, Benzodiazepine GABA,Receptors, GABA A,Receptors, GABA Benzodiazepine,delta Subunit, GABA A Receptor,epsilon Subunit, GABA A Receptor,gamma Aminobutyric Acid Subtype A Receptors
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001345 Autoradiography The making of a radiograph of an object or tissue by recording on a photographic plate the radiation emitted by radioactive material within the object. (Dorland, 27th ed) Radioautography
D001643 Bridged Bicyclo Compounds Saturated alicyclic hydrocarbon molecules consisting of two rings that have two non-adjacent atoms in common. Bicyclo Compounds,Bicyclo Compounds, Bridged
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity

Related Publications

S Y Sakurai, and A Kume, and D E Burdette, and R L Albin
September 1985, Journal of neurochemistry,
S Y Sakurai, and A Kume, and D E Burdette, and R L Albin
June 1996, The Journal of pharmacology and experimental therapeutics,
S Y Sakurai, and A Kume, and D E Burdette, and R L Albin
December 1993, Journal of neurochemistry,
S Y Sakurai, and A Kume, and D E Burdette, and R L Albin
October 1998, European journal of pharmacology,
S Y Sakurai, and A Kume, and D E Burdette, and R L Albin
May 1978, Proceedings of the National Academy of Sciences of the United States of America,
S Y Sakurai, and A Kume, and D E Burdette, and R L Albin
February 1989, Molecular pharmacology,
S Y Sakurai, and A Kume, and D E Burdette, and R L Albin
June 1985, Neuroscience letters,
S Y Sakurai, and A Kume, and D E Burdette, and R L Albin
September 1981, Molecular pharmacology,
S Y Sakurai, and A Kume, and D E Burdette, and R L Albin
December 1978, Proceedings of the National Academy of Sciences of the United States of America,
S Y Sakurai, and A Kume, and D E Burdette, and R L Albin
December 1983, Journal of neurochemistry,
Copied contents to your clipboard!